Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | IAPP | P10997 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | PTGER3 | P43115 | 7/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 7/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.46 |
| ▸ | TBXA2R | P21731 | 4/20 | 0.44 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26046363 | 0.87 | LMNA (0.59) | LMNAMAPTKDM4EIAPPGLA | |
| SCHEMBL15630767 | 0.85 | LMNA (0.58) | LMNAMAPTKDM4EIAPPGLA | |
| SCHEMBL3214322 | 0.85 | PTGER3 (0.63) | MAPTPTGER3PTGER2PTGER4TBXA2R | |
| SCHEMBL1150939 | 0.85 | PTGER3 (0.63) | MAPTPTGER3PTGER2PTGER4TBXA2R | |
| SCHEMBL309761 | 0.85 | PTGER3 (0.63) | MAPTPTGER3PTGER2PTGER4TBXA2R | |
| SCHEMBL9725168 | 0.84 | LMNA (0.53) | LMNAMAPTKDM4EIAPPGLA | |
| SCHEMBL14441077 | 0.83 | MAPT (0.76) | LMNAMAPTKDM4EIAPPGLA | |
| SCHEMBL27680267 | 0.83 | PTGER3 (0.45) | LMNAMAPTKDM4EIAPPPTGER3 | |
| SCHEMBL27667797 | 0.83 | PTGER3 (0.45) | LMNAMAPTKDM4EIAPPPTGER3 | |
| SCHEMBL5695994 | 0.82 | LMNA (0.54) | LMNAMAPTKDM4EIAPPGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447090-B2 | Imidazopyridine compounds | ASTELLAS PHARMA INC. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-20140088080-A1 | IMIDAZOPYRIDINE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2014-03-27 | — | — | US | disclosed |
| EP-2144889-B1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2012-08-29 | — | — | EP | disclosed |
| US-7314879-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2008-01-01 | — | — | US | disclosed |
| US-7291619-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-7186715-B2 | Piperazine- and piperidine-derivatives as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-03-06 | — | — | US | disclosed |
| US-7169777-B2 | Melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-7157463-B2 | Substituted piperidines/piperazines as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088080-A1 | IMIDAZOPYRIDINE COMPOUNDS | GUCY1A1, PDE2A, GUCY1A2 | LMNA 1848/4885MAPT 4789/4885KDM4E 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.